Prediction of metastatic pheochromocytoma and paraganglioma: a machine learning modelling study using data from a cross-sectional cohortChristina Pamporaki, Graeme Eisenhofer, Mercedes Robledo et al.|The Lancet Digital Health|2023Cited by 70
Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trialÉric Baudin, Anouk van Berkel, Bernard Goichot et al.|The Lancet|2024Cited by 69
Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic ResponsesAlessa Fischer, Svenja Nölting, Simon Kloos et al.|The Journal of Clinical Endocrinology & Metabolism|2023Cited by 48
Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paragangliomaChristina Pamporaki, Graeme Eisenhofer, Tamara Prodanov et al.|European Journal of Cancer|2022Cited by 43
Recurrent Disease in Patients With Sporadic Pheochromocytoma and ParagangliomaMinghao Li, Christina Pamporaki, Tamara Prodanov et al.|The Journal of Clinical Endocrinology & Metabolism|2022Cited by 36